Clinical Trials Logo

Glioma of Brain clinical trials

View clinical trials related to Glioma of Brain.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03927274 Terminated - Glioma of Brain Clinical Trials

Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma

Start date: June 20, 2019
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine if treatment with Topotecan by an alternative method, delivering topotecan directly into brain tumors, is safe and well tolerated.

NCT ID: NCT03698201 Terminated - Glioma of Brain Clinical Trials

Blood Biomarker Signature in Glioma

Start date: July 2009
Phase:
Study type: Observational

This is an exploratory, translational and non-interventional clinical study. The aim of this study is to identify a blood biomarker signature for glioma.

NCT ID: NCT03698162 Terminated - Metastatic Melanoma Clinical Trials

Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases

Start date: April 13, 2021
Phase: N/A
Study type: Interventional

Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised. This trial studies how well precise DCE MRI works in diagnosing participants with high grade glioma that has come back or melanoma that has spread to the brain. The specially-tailored acquisition and reconstruction (STAR) DCE MRI could provide improved assessment of brain tumor status and response to therapy.

NCT ID: NCT03436433 Terminated - Glioma Clinical Trials

Seizure Prophylaxis in Patients With Glioma or Brain Metastasis

Start date: January 31, 2019
Phase: Phase 2
Study type: Interventional

This protocol is designed to assess the need for seizure prophylaxis in the perioperative period for patients undergoing neurosurgical procedure (gross-total resection, sub-total resection or biopsy) for suspected diagnosis of new, recurrent or transformed glioma (WHO grade I-IV) and brain metastasis. This will be determined by observing the impact of Lacosamide (LCM), Levetiracetam (LEV), or no anti-epileptic drug (AED) on whether visits to the emergency department (ED) or hospital re-admissions occur within 30 days after procedure. A secondary endpoint will evaluate the safety and tolerability of LCM and LEV. Exploratory endpoints will evaluate admission duration for the procedure, number of post-operative provider communications (telephone, email, and additional clinic encounters, etc.), and patient risk factors associated with post-operative seizure.